Top Markets
Coin of the day
Boston Scientific Corporation Boston Scientific Corporation

Boston Scientific Corporation

BSX
Rangering i aksjer #210
Boston Scientific Corporation develops, manufactures, and markets medical... Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Aksjekurs
$62.83
Markedsverdi
$93.23B
Endring (1 dag)
-9.17%
Endring (1 år)
-31.36%
Land
US
Handel Boston Scientific Corporation (BSX)

Kategori

P/E-forhold for Boston Scientific Corporation (BSX)
P/E-forhold per April 2026 TTM: 32.19
Ifølge Boston Scientific Corporation sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 32.19. Ved slutten av 2024 hadde selskapet en P/E på 70.89.
P/E-forholdshistorikk for Boston Scientific Corporation fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 32.19 -34.18%
2025 48.91 -31.01%
2024 70.89 34.45%
2023 52.73 -44.39%
2022 94.83 63.23%
2021 58.10 -109.35%
2020 -621.10 -4,739.24%
2019 13.39 -54.16%
2018 29.21 -91.06%
2017 326.58 285.92%
2016 84.63 -182.61%
2015 -102.44 -30.52%
2014 -147.45 10.67%
2013 -133.23 6,624.20%
2012 -1.98 -110.84%
2011 18.28 -269.40%
2010 -10.79 -18.52%
2009 -13.24 132.42%
2008 -5.70 -83.69%
2007 -34.93 471.06%
2006 -6.12 -118.98%
2005 32.22 15.12%
2004 27.99 -56.60%
2003 64.49 39.54%
2002 46.22 -124.91%
2001 -185.54 -1,347.09%
2000 14.88 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
27.47 -14.67%
US
38.72 20.27%
US
24.08 -25.21%
IE
24.08 -25.21%
IE
19.12 -40.60%
DE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.